Prodia Strengthens Stem Cell Services and Expands Regionally to Boost 2026 Performance

Strategic Investment in Stem Cell Therapy

PT Prodia Widyahusada Tbk (PRDA) is maintaining a positive outlook for its 2026 performance following strategic investments in innovative healthcare services. The company's investment in PT Prodia Stemcell Indonesia (ProSTEM), where it holds a 30% stake, has strengthened its position in the stem cell therapy market. This investment aligns with Prodia's long-term vision to provide personalized, precise, and high-value healthcare services.

Key Focus Areas for Growth

Prodia's management has outlined several key areas to support the growth of its stem cell therapy business. These include enhancing supporting services for stem cell therapy at Prodia clinics, with a particular focus on research and development (R&D) to improve treatment efficacy and safety. The company also plans to integrate regenerative therapy-based clinical services, ensuring a comprehensive approach to patient care. Additionally, Prodia will prioritize scientific education to promote awareness and understanding of stem cell therapy among healthcare professionals and patients.

Business Expansion and Regional Presence

The company's strategic expansion into regional markets is expected to drive growth and increase its market share in the healthcare sector. By leveraging its innovative healthcare services and strengthening its regional presence, Prodia is well-positioned to achieve its business objectives in 2026 and beyond.